Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall resp...
Main Authors: | António Almeida, Ana Rita Ferreira, Maria João Costa, Sofia Silva, Khalil Alnajjar, Isabel Bogalho, Francesca Pierdomenico, Susana Esteves, Mafalda Alpoim, Gil Braz, Emilia Cortesão, Ricardo Pinto |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-01-01
|
Series: | Leukemia Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048916300486 |
Similar Items
-
Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
by: Guangjie Zhao, et al.
Published: (2021-09-01) -
Clinical Results of Hypomethylating Agents in AML Treatment
by: Marjan Cruijsen, et al.
Published: (2014-12-01) -
Hypomethylating Agents in Oncohematology
by: AD Shirin,, et al.
Published: (2016-10-01) -
Biomodulatory Treatment With Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis
by: Sebastian Klobuch, et al.
Published: (2018-11-01) -
Acute Myeloblastic Leukemia and Myelodysplastic Syndrome: Azacitidine for Prophylactic and Preventive Purposes after Allogeneic Hematopoietic Stem Cell Transplantation
by: VN Ovechkina, et al.
Published: (2017-01-01)